

Patrizia Casalini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11538864/publications.pdf>

Version: 2024-02-01

40
papers

4,423
citations

201385

27
h-index

329751

37
g-index

40
all docs

40
docs citations

40
times ranked

7131
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA Signatures in Human Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 8699-8707.	0.4	1,356
2	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. <i>Blood</i> , 2012, 120, 3007-3018.	0.6	350
3	microRNA-205 Regulates HER3 in Human Breast Cancer. <i>Cancer Research</i> , 2009, 69, 2195-2200.	0.4	334
4	FOXP3 Expression and Overall Survival in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1746-1752.	0.8	271
5	Role of HER receptors family in development and differentiation. <i>Journal of Cellular Physiology</i> , 2004, 200, 343-350.	2.0	201
6	Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node-Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables. <i>Journal of Clinical Oncology</i> , 2001, 19, 329-335.	0.8	147
7	Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. <i>Molecular Oncology</i> , 2012, 6, 458-472.	2.1	142
8	MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. <i>European Journal of Cancer</i> , 2008, 44, 2753-2759.	1.3	138
9	Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. <i>Cancer Letters</i> , 2017, 384, 94-100.	3.2	131
10	Conversion to stem cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. <i>Molecular Oncology</i> , 2016, 10, 253-271.	2.1	120
11	Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. <i>Cancer Discovery</i> , 2014, 4, 110-129.	7.7	100
12	Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification. <i>International Journal of Cancer</i> , 1991, 47, 933-937.	2.3	99
13	HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 458-462.	0.8	99
14	Breast cancer and microRNAs: therapeutic impact. <i>Breast</i> , 2011, 20, S63-S70.	0.9	87
15	FOXP3 expression in tumor cells and implications for cancer progression. <i>Journal of Cellular Physiology</i> , 2013, 228, 30-35.	2.0	87
16	miR-9 and miR-200 Regulate PDGFR β -Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2016, 76, 5562-5572.	0.4	74
17	Redirected Activity of Human Antitumor Chimeric Immune Receptors is Governed by Antigen and Receptor Expression Levels and Affinity of Interaction. <i>Journal of Immunotherapy</i> , 2007, 30, 684-693.	1.2	70
18	SPARC Oppositely Regulates Inflammation and Fibrosis in Bleomycin-Induced Lung Damage. <i>American Journal of Pathology</i> , 2011, 179, 3000-3010.	1.9	62

#	ARTICLE	IF	CITATIONS
19	HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. <i>Clinical Cancer Research</i> , 2002, 8, 520-5.	3.2	58
20	Immunological and pathobiological roles of fibulin-1 in breast cancer. <i>Oncogene</i> , 2004, 23, 2153-2160.	2.6	45
21	Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. <i>Breast Cancer Research and Treatment</i> , 1999, 55, 167-175.	1.1	44
22	Role of p53 in HER2-induced Proliferation or Apoptosis. <i>Journal of Biological Chemistry</i> , 2001, 276, 12449-12453.	1.6	44
23	Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. <i>PLoS ONE</i> , 2013, 8, e56761.	1.1	41
24	PDGFR β and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. <i>Molecular Oncology</i> , 2014, 8, 968-981.	2.1	37
25	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. <i>Oncolmmunology</i> , 2014, 3, e28989.	2.1	34
26	Expression of Concern: HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA. <i>Journal of Cellular Physiology</i> , 2004, 200, 82-88.	2.0	31
27	Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 1768-1779.	2.0	31
28	CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. <i>Oncotarget</i> , 2016, 7, 69649-69665.	0.8	29
29	Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: Analysis of cell binding and internalization. <i>International Journal of Cancer</i> , 1991, 48, 284-290.	2.3	20
30	Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact. <i>Clinical Cancer Research</i> , 2008, 14, 25-31.	3.2	20
31	Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression. , 1997, 72, 631-636.		19
32	Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. <i>Scientific Reports</i> , 2019, 9, 14288.	1.6	17
33	Relationship between p53 and p27 expression following HER2 signaling. <i>Breast</i> , 2007, 16, 597-605.	0.9	16
34	The PDGFR β /ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 586.	1.1	16
35	Differential sensitivity of CD30+neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies. <i>British Journal of Haematology</i> , 1995, 90, 572-577.	1.2	14
36	MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. <i>Oncotarget</i> , 2018, 9, 27920-27928.	0.8	14

#	ARTICLE	IF	CITATIONS
37	Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells. Journal of Cellular Physiology, 2015, 230, 2661-2670.	2.0	13
38	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. European Journal of Cancer, 2006, 42, 1057-1061.	1.3	8
39	microRNA: New Players in Metastatic Process. , 2013, , .		2
40	Current and Future Developments in Cancer Therapy Research: miRNAs as New Promising Targets or Tools. , 2012, , 517-546.		2